2026-08-14
A core pharmaceutical arm of Suzhou Tianma Pharma Group, Suzhou Tianji Biopharma has specialized in peptide therapeutics for more than 26 years, with a fully integrated value chain spanning peptide APIs and finished dosage forms. Our pipeline spans high-growth franchises, including Tirzepatide, Semaglutide, and other GLP-1 receptor agonists; the oral cyclic peptide Linaclotide; and Peptide-Drug Conjugates (PDCs).
New Production Campus – Changshu New Materials Industrial Park
Metric | Detail |
Site Area | 80 mu (~5.3 hectares) |
Total GFA | 53,564 m² |
API Workshops | 4 international-standard units (2 peptide APIs + 2 small-molecule APIs) |
Formulation Workshops | 6 GMP-compliant integrated lines |
Dedicated Topical Unit | 1,500 m² (planned) |
Designed and built to global regulatory standards — cGMP, FDA, ICH, and EMA.
Production Capacity Highlights
Category | Capacity & Specs |
Peptide APIs | Annual output ≥ 2,000 kg; Synthesizers: 10L–3,000L; Batch scale: 100g to tens of kg |
Small-Molecule APIs | Reactors: 500L–5,000L; Temp range: –20°C to 145°C; Batch scale up to metric ton level |
Injectables | >300 million units/year (≥200M lyophilized vials + ≥100M small-volume injections) |
Topical Dosage Forms | Additional hormonal/non-hormonal capacity in pipeline |
Strategic Advantages
· Location: Yangtze River Delta hub — superior logistics and supply-chain connectivity
· Scale: Metric-ton API capacity paired with 100M+ units of annual formulation output
· Compliance: Automated, validated manufacturing lines meeting major global regulatory standards